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ABSTRACT JMJD3 H3K27me3 demethylase plays an important role in the transcriptional 
response to different signaling pathways; however, the mechanism by which it facilitates 
transcription has been unclear. Here we show that JMJD3 regulates transcription of trans-
forming growth factor β (TGFβ)–responsive genes by promoting RNA polymerase II (RNAPII) 
progression along the gene bodies. Using chromatin immunoprecipitation followed by se-
quencing experiments, we show that, upon TGFβ treatment, JMJD3 and elongating RNAPII 
colocalize extensively along the intragenic regions of TGFβ target genes. According to these 
data, genome-wide analysis shows that JMJD3-dependent TGFβ target genes are enriched 
in H3K27me3 before TGFβ signaling pathway activation. Further molecular analyses demon-
strate that JMJD3 demethylates H3K27me3 along the gene bodies, paving the way for the 
RNAPII progression. Overall these findings uncover the mechanism by which JMJD3 facili-
tates transcriptional activation.
INTRODUCTION
Cellular identity and function are determined by a combination of 
signaling pathways that converge on chromatin to regulate the 
transcription of specific sets of genes. Thus chromatin is the final 
platform where cellular signals are integrated in order to control 
gene transcriptional programs. Chromatin accessibility is regulated 
by epigenetic mechanisms, particularly by covalent histone modi­
fications. Among these, methylation of Lys­27 of histone H3 
(H3K27me3) has been found to be a key regulator of cell homeo­
stasis and embryonic development (Morey and Helin, 2010; 
Margueron and Reinberg, 2011). Enhancer of Zeste Homologues 1 
and 2 (EZH1/2) are the enzymes responsible for the H3K27 methy­
lation reaction (Cao et al., 2002; Czermin et al., 2002; Kuzmichev 
et al., 2002). They are part of Polycomb repressive complex 2 
(PRC2), which, together with the PRC1 complex, establishes the 
repressive state associated with H3K27me3 marks (Cao et al., 
2002; Lois et al., 2010). Although H3K27me3 has been described 
as a stable histone mark, recent findings show that two new his­
tone demethylase (HDM) enzymes, JMJD3 and UTX, can cause this 
modification to revert (Agger et al., 2007; De Santa et al., 2007; 
Lan et al., 2007; Lee et al., 2007). Both JMJD3 and UTX contain a 
Jumonji C (JmjC) domain responsible to the HDM catalytic activity 
(Agger et al., 2007; De Santa et al., 2007; Lan et al., 2007; Lee 
et al., 2007). These two genes play an essential role during devel­
opment, as many key developmental promoters are often marked 
by H3K27me3 (Boyer et al., 2006; Bracken et al., 2006; Lee et al., 
2006; Pan et al., 2007). In particular, they derepress HOX genes 
and a subset of neural and epidermal differentiation genes (Agger 
et al., 2007; Jepsen et al., 2007; Lan et al., 2007; Lee et al., 2007; 
Burgold et al., 2008; Sen et al., 2008). Moreover, it has recently 
been shown that JMJD3 cooperates with transforming growth fac­
tor β (TGFβ) and bone morphogenic protein signaling pathways to 
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JMJD3 associates with H3K27me3 gene bodies 
in TGFβ-stimulated NSCs
The results described in the preceding section suggest that H3K27 
methylation/demethylation at the transcribing regions might play a 
pivotal role in TGFβ response. To test this hypothesis, we investi­
gated the binding sites of JMJD3 in NSCs treated with TGFβ by 
ChIP­seq (Figure 2A). We first checked the efficiency of the JMJD3 
antibody used in our experimental conditions (Supplemental Figure 
S2A). After sequencing of JMJD3­associated DNA fragments, we 
identified 61,610 peaks. In agreement with previous data (Estarás 
et al., 2012) and consistent with what was identified in other cell 
contexts (De Santa et al., 2009), JMJD3 peaks were distributed 
across the intergenic and intragenic regions (Figure 2B and Supple­
mental Figure S2B).
Next we compared the distribution of JMJD3 around TSS, TES, 
and gene bodies between JDTA genes and the remaining genes in 
the array. Results in Figure 2C show that the former exhibited higher 
levels of bound JMJD3 both in TSS and gene bodies. Remarkably, 
JMJD3 was distributed along the intragenic regions until the TES 
(Figure 2C).
We then examined whether JMJD3 binds H3K27me3 gene bod­
ies upon TGFβ treatment. We observed that JMJD3 associates with 
the 90.9% of methylated genes (Figure 2D, orange box), suggesting 
that JMJD3 is recruited to these regions upon signal activation.
To further explore this idea, we tested whether TGFβ signal was 
required to recruit JMJD3 to gene bodies by ChIP followed by qPCR 
experiments. Results in Figure 2, E and F, show that, 3 h after TGFβ 
treatment, JMJD3 was recruited to the intragenic regions of the 
TGFβ­responsive gene neurogenin 2 (Neurog2; Estarás et al., 2012). 
This recruitment was not observed for the gene G6pd2 (Figure 2, E 
and F), a non–TGFβ­regulated gene used as a negative control. Of 
interest, Smad3 was not targeted to the intragenic region upon 
TGFβ treatment, suggesting that JMJD3 binding to the gene bod­
ies is not led by Smad3 (Supplemental Figure S3A), in contrast to 
what was found for promoters (Estarás et al., 2012). In addition, 
TGFβ signaling did not affect JMJD3 subcellular distribution (Sup­
plemental Figure S3B). These findings reinforce the idea that the 
binding of JMJD3 to the intragenic regions facilitates transcription.
Because our data indicate that JDTA genes are enriched in 
H3K27me3 before TGFβ activation (Figure 2D), we tested whether 
the binding of JMJD3 to intragenic regions leads to H3K27me3 
demethylation. To this end, we analyzed changes in H3K27me3 lev­
els along the Neurog2 gene body upon TGFβ activation. Results in 
Figure 2G indicate that H3K27me3 levels decreased 3 h after cy­
tokine addition in the analyzed regions. To further characterize the 
contribution of JMJD3 to the observed demethylation, we analyzed 
the H3K27me3 levels in JMJD3 KD cells. As shown in Supplemental 
Figure S3C, no significant changes were detected in H3K27me3 lev­
els in TGFβ­stimulated JMJD3 KD cells. These data demonstrate 
that the H3K27me3 demethylation observed in the intragenic re­
gions of JDTA genes in control cells is dependent on JMJD3. This is 
supported by ChIP­seq data analysis, showing an overall lack of co­
incidence between nucleotides bound by H3K27me3 and JMJD3 
(Supplemental Figure S3D). In summary, these results support the 
notion that JMJD3 association with gene bodies promotes 
H3K27me3 demethylation.
JMJD3 interacts with RNAPII-S2p
The results described here reveal an enrichment in JMJD3 along the 
gene body for JDTA genes. This suggests that JMJD3 might be in­
volved in RNAPII elongation. To explore this hypothesis, we investi­
gated the association of JMJD3 with elongating RNAPII. Using 
control neuronal differentiation and cell fate specification in early 
neural development (Akizu et al., 2010; Estarás et al., 2012). These 
findings point to an important role of JMJD3 and UTX, and hence 
H3K27me3 demethylation, in transcriptional regulation of specific 
signaling pathways. However, the mechanism by which these en­
zymes facilitate transcription remains unclear. Of interest, genome­
wide analyses recently showed that JMJD3 binds to promoters, 
but also to gene bodies, in neural stem cells (NSCs; Estarás et al., 
2012) and macrophages (De Santa et al., 2009). In addition, it has 
been reported that UTX localizes at the intragenic regions of mus­
cle­specific genes during myogenesis (Seenundun et al., 2010). 
Moreover, recent data indicate that the H3K27me3 pattern moves 
from promoters to intragenic regions after cell differentiation 
(Hawkins et al., 2010). When considered together, these data led 
us to hypothesize that H3K27me3 HDMs might play an important 
role at intragenic regions in transcriptional response to signaling 
pathway activation.
To address this hypothesis, we analyzed the contribution of 
gene­body–associated JMJD3 to TGFβ transcriptional response. 
Our data demonstrate that JMJD3 is required to promote transcrip­
tion elongation by demethylating H3K27me3 at the transcribed re­
gions of TGFβ­responsive genes.
RESULTS
Genome-wide H3K27me3 distribution in NSCs
Genome­wide analysis has shown that JMJD3 localizes on gene 
bodies in TGFβ­stimulated NSCs (Estarás et al., 2012). However, we 
still do not know how the association of JMJD3 to intragenic regions 
contributes to TGFβ­mediated transcriptional response. To address 
this problem, we first analyzed the global H3K27me3 profile in NSCs 
by applying the chromatin immunoprecipitation followed by se­
quencing (ChIP­seq) technique (Figure 1A). First, we validated the 
H3K27me3 antibody by ChIP, followed by quantitative PCR (qPCR) 
of two well­known H3K27me3 targets and a negative control (Sup­
plemental Figure S1A). Using the same conditions, we performed 
H3K27me3 ChIP assays; then libraries were generated and se­
quenced with an Illumina Genome Analyzer II. The total number of 
peaks detected after input normalization was 16,168.
We then examined the genomic distribution of the H3K27me3 
peaks. Our results, in accordance with findings from other cell 
contexts (Hawkins et al., 2010; Kim et al., 2011), showed that the 
H3K27me3 mark is abundant within the intragenic regions (Figure 
1B). More precisely, we identified 5009 H3K27me3 peaks along 
the gene bodies and 982 around the transcription start site (TSS; 
defined as ±1000 base pairs; Figure 1C). These results are in good 
agreement with previous data on specified cells (Hawkins et al., 
2010), showing that H3K27me3­binding sites are spread along the 
intragenic regions and decrease around the transcription end site 
(TES; Figure 1, D and E). A different distribution was described for 
embryonic stem cells (Barski et al., 2007; Mikkelsen et al., 2007), 
in which H3K27me3 is mainly localized around the TSS and 
promoters.
We previously showed that JMJD3 is essential to activate a set of 
TGFβ­induced genes in NSCs (Estarás et al., 2012, and Figure 1F). 
To characterize the dynamics of H3K27 methylation, we analyzed 
the H3K27me3 levels in the set of TGFβ­responsive genes that 
require JMJD3 to be activated (fold change [FC] ≥ 1.5, p ≤ 0.05; 
61 genes), from now on abbreviated as JDTA genes (Figure 1F and 
Supplemental Table S1). Results in Figure 1G and Supplemental 
Figure S1B show that JDTA genes (Figure 1G, orange box) are en­
riched in H3K27me3 compared with the remaining genes in the ar­
ray (20,636; Figure 1G, green box, and Supplemental Figure S1B).
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FIGURE 1: Genome-wide H3K27me3 distribution in NSCs. (A) The ChIP-seq experimental procedure. (B) Genomic 
distribution of H3K27me3-binding sites in NSCs. (C) Number of H3K27me3 peaks distributed along the TSS and gene 
bodies in NSCs. (D) Metagene profile of H3K27me3 in NSCs. To construct a metagene profile, gene bodies were scaled 
to 3 kb (see Materials and Methods). (E) Representation of H3K27me3 coverage by normalized wig files for the 
indicated RefSeq genes. Right numbers represent the length of the visualized region in kilobases. Left numbers indicate 
the scale of the Y axis (minimum and maximum numbers of reads). (F) Schematic representation of microarray analysis 
design to identify JDTA genes in NSCs. (G) Percentage of genes with H3K27me3 peaks on the gene body within the set 
of JDTA genes (orange box) and in the remaining genes in the array (green box).
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FIGURE 2: JMJD3 is recruited to the intragenic regions upon TGFβ signal. (A) The ChIP-seq experimental procedure. 
(B) Genomic distribution of JMJD3-binding sites in TGFβ-stimulated NSCs. (C) Metagene profiles of JMJD3 coverage for 
JDTA genes and for the remaining genes in the array (orange and green boxes, respectively) in TGFβ-stimulated NSCs. 
(D) Middle, schematic representation showing percentage of genes with H3K27me3 peaks within JDTA genes (orange 
box) or the remaining genes in the array (green box). Right, percentage of H3K27me3-enriched gene bodies bound by 
JMJD3 for JDTA genes (orange box) or for the remaining genes in the array (green box). (E) Schematic representation of 
the neurogenin 2 locus. The encircled numbers under the scheme indicate the location of the primer sets used in the 
ChIP experiments. (F, G) JMJD3 (F) and H3K27me3 (G) ChIP assays analyzed by qPCR performed in NSCs untreated 
(white bars) or TGFβ treated (3 h; gray bars). Regions analyzed for the neurogenin 2 locus and the negative control gene 
(G6pd2) are indicated in the x-axis. Mock (immunoglobulin G ChIP) signals were subtracted from specific enrichment 
values. Three biological replicates were used in each ChIP experiment. Error bars indicate SD. *p < 0.05; **p < 0.01.
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intragenic regions, in agreement with RNAPII­S2p–elongating func­
tion (Figure 3D).
Because we were interested in JMJD3 association with RNAPII­
S2p in JDTA genes, we investigated the occupancy of both fac­
tors on their gene bodies. We analyzed the number of genes that 
associate both JMJD3 and RNAPII­S2p factors. We observed 
JMJD3 bound to most of RNAPII­S2p–positive genes (Figure 3E). 
It is striking that high­resolution analysis showed that, on gene 
bodies, 46.72% of the nucleotides occupied by RNAPII­S2p were 
shared with JMJD3 (Figure 3G, orange box) in JDTA genes. This 
figure dropped to 18.89% for the remaining genes in the array 
(Figure 3G, green box). Similarly, 68.8% of RNAPII­S2p peaks 
(52 of 77) colocalize with JMJD3 peaks in the coding region of the 
JDTA genes (Supplemental Figure S4B). Figure 3F shows the co­
localization of RNAPII­S2p and JMJD3 for five genes from the set 
of JDTA genes.
Taken together, these results indicate that, in TGFβ­stimulated 
NSCs, JMJD3 and RNAPII­S2p are broadly associated and distrib­
uted along the gene bodies of JDTA genes.
coimmunoprecipitation (CoIP) experiments, we found that overex­
pressed JMJD3 interacts with the elongating form of RNAPII (phos­
phorylated at Ser­2; RNAPII­S2p) but not with unphosphorylated 
RNAPII (Figure 3A). We confirmed this result by CoIP experiments 
with endogenous proteins, which showed that JMJD3 and RNAPII­
S2p interact in NSCs (Figure 3B), pointing to the possibility that 
JMJD3 forms part of the elongating complex.
JMJD3 and RNAPII colocalize along the gene bodies 
of TGFβ target genes
The ability of the JMJD3 and RNAPII­S2p to coimmunoprecipitate 
suggests that both factors could bind a subset of common target 
genes. To investigate this possibility, we identified the genomic 
binding sites of RNAPII­S2p in TGFβ­treated NSCs by sequencing 
DNA fragments of immunoprecipitated chromatin (Figure 3C). To 
perform the ChIP­seq experiment, we used a ChIP­grade antibody 
that efficiently immunoprecipitates the RNAPII­S2p form (Supple­
mental Figure S4A). We obtained 24,997 peaks for RNAPII­S2p after 
input normalization. Most of the peaks were associated with the 
FIGURE 3: JMJD3 and RNAPII colocalize on TGFβ-regulated genes. (A, B) Immunoprecipitation of overexpressed 
Myc-JMJD3 (A) or endogenous JMJD3 (B) was performed using 293t (A) or NSC (B) total extracts. RNAPII or RNAPII-
S2p were detected by immunoblotting. Input corresponds to 1% of the total protein present in the whole-cell extract. 
(C) The ChIP-seq experimental procedure. (D) Genomic distribution of RNAPII-S2p binding sites in TGFβ-stimulated 
NSCs. (E) Venn diagram showing the number of gene bodies cobound by JMJD3 and RNAPII-S2p from the set of JDTA 
genes. (F) Representation of RNAPII-S2p and JMJD3 coverage by normalized wig files for the indicated RefSeq genes. 
Right numbers represent the length of the visualized region. Left numbers indicate the scale of the y-axis (number of 
reads). (G) Overlapping nucleotides between RNAPII-S2p and JMJD3 from the set of JDTA genes (orange box) and the 
rest of the genes (green box).
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moters. To do that, we performed Cdk9 ChIP­qPCR experiments in 
C KD and JMJD3 KD cell lines in the absence and presence of TGFβ. 
The results (Supplemental Figure S5A) showed that Cdk9 is recruited 
to the Neurog2 promoter in TGFβ­stimulated control cells. Never­
theless, the low levels of JMJD3 significantly affected Cdk9 binding 
to the Neurog2 gene. These findings are in accordance with the lack 
of RNAPII­S2P observed in JMJD3 KD cells (Figure 4D). It is worth 
mentioning that the observed effect of JMJD3 on transcription is 
not because JMJD3 influences Smad3 binding to promoters 
(Estarás et al., 2012) or affects Smad3 translocation into the nucleus 
upon TGFβ treatment (Supplemental Figure S5B). Overall these 
observations suggested that JMJD3 is required to allow RNAPII 
progression through the Neurog2 gene body (Figure 4D).
JMJD3 binding to gene bodies depends 
on active transcription
The experiments described here showed that JMJD3 is distrib­
uted along the gene bodies of TGFβ­activated genes in associa­
tion with RNAPII­S2p. We then sought to investigate whether the 
presence of JMJD3 in the intragenic regions require active tran­
scription. To this end, we treated NSCs with DRB, a pharmacologi­
cal inhibitor of transcriptional elongation. We first confirmed that 
under our experimental conditions (DRB, 75 μM, 4 h, added 1 h 
before TGFβ cytokine treatment), 1) DRB treatment blocked 
RNAPII Ser­2 phosphorylation (Figure 5A), and 2) TGFβ induced 
expression of the gene under study (Figure 5B). In addition, to rule 
out any nonspecific effect of the drug on TGFβ response, we con­
firmed that it did not affect Smad3 translocation into the nucleus 
after TGFβ stimulation (Figure 5C). We then examined JMJD3 
JMJD3 is essential for RNAPII elongation
To assess whether colocalization of JMJD3 with RNAPII­S2p plays 
any role in stimulating transcription, we analyzed the recruitment of 
RNAPII in the presence or absence of JMJD3, using C KD and 
JMJD3 KD NSCs. Then we performed ChIP assays on a JDTA gene 
(Neurog2) and a negative control gene (G6pd2) for both C KD and 
JMJD3 KD NSCs (Figure 4A and Estarás et al., 2012) to investigate 
the RNAPII recruitment on Neurog2 promoter upon TGFβ treat­
ment, using an antibody that recognizes the N­terminus of RNAPII 
(N20). Results in Figure 4B indicate that RNAPII was targeted to the 
Neurog2 promoter in the C KD cell line 0.5 h after TGFβ activation. 
Of interest, we observed similar behavior for RNAPII promoter as­
sociation in the JMJD3 KD cell line (Figure 4B). These findings dem­
onstrate that JMJD3 is not essential for RNAPII initial targeting to 
promoters.
Then we tested whether JMJD3 affects the levels of elongating 
RNAPII at transcribing regions upon TGFβ treatment. ChIP assays 
showed a clear enrichment in RNAPII­S2p on the Neurog2 gene af­
ter TGFβ treatment in C KD cells, correlating with mRNA accumula­
tion (Figure 4A). Of interest, this RNAPII­S2p recruitment was absent 
in JMJD3 KD cells (Figure 4C), in agreement with the lack of active 
transcription (Figure 4A). To further understand the influence of 
JMJD3 on RNAPII­S2p, we analyzed the recruitment of the P­TEFb 
elongation factor. The catalytic subunit of P­TEFb complex is Cdk9, 
which phosphorylates Ser­2 of the CTD domain of RNAPII. Apart 
from its extensive role as an essential factor for transcription elonga­
tion (Peterlin and Price, 2006), it was also found that Cdk9 phospho­
rylates Smad3, promoting its activity (Alarcon et al., 2009). On that 
basis, we tested whether JMJD3 regulates Cdk9 binding to the pro­
FIGURE 4: JMJD3 is essential for RNAPII elongation. (A) Relative mRNA levels of neurogenin 2 in C KD and JMJD3 KD 
NSCs untreated or treated with TGFβ for the times indicated in the legend. (B, C) ChIP assays analyzed by qPCR 
performed in C KD and JMJD3 KD NSC lines before (0 h) and after (0.5 and 3 h) TGFβ treatment using total RNAPII 
(N20; B) or RNAPII-S2p (ab5095; C) antibodies. Analyzed gene regions are indicated in the corresponding scheme. 
Normalized basal conditions and fold recruitment upon TGFβ treatment in C KD and JMJD3 KD cell lines are 
represented. (D) Summary of the results. In TGFβ-stimulated C KD cells the transcription machinery is uploaded to the 
promoters and spreads within the body of genes to generate new mRNA. In TGFβ-stimulated JMJD3 KD cells, the 
recruitment of RNAPII to promoters occurs to the same extent as in control cells, but the RNAPII progression along the 
gene bodies is impaired.
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regulates the transcription of TGFβ­responsive genes by allowing 
RNAPII progression through the gene bodies. We demonstrate that 
the contribution of JMJD3 to transcription not only occurs at the 
promoter level (Estarás et al., 2012), but also requires migration of 
JMJD3 to the H3K27me3 intragenic regions to regulate the process 
of transcriptional elongation (Figure 5E). The correlation between 
JMJD3 presence on gene bodies and H3K27me3 demethylation 
suggests that active demethylation at transcribing regions is impor­
tant for RNAPII progression.
Our data show the existence of broad domains of H3K27me3 
enrichment along the gene bodies. Similar data were previously re­
ported (Hawkins et al., 2010; Young et al., 2011), showing that 
H3K27me3 domains are expanded on committed cells. Our study 
not only confirms the H3K27me3 expansion along the transcribing 
regions, but it also sheds light on the mechanism by which intragenic 
H3K27me3 demethylation is coupled to transcriptional elongation. 
recruitment within the transcribing regions upon TGFβ treatment. 
Analysis of JMJD3 ChIP in Figure 5D shows that TGFβ­induced 
JMJD3 enrichment within the gene body was impaired in the 
presence of DRB. Of interest, DRB treatment blocked specifically 
JMJD3 association to the intragenic regions, since JMJD3 binding 
to promoter was not affected (Figure 5D, region 1). These data 
demonstrate that the presence of JMJD3 in the gene bodies is 
linked to active transcription.
Overall these findings strongly support that JMJD3 HDM has a 
key role in gene bodies in allowing transcription elongation to 
proceed.
DISCUSSION
Our results provide new insights into the transcriptional regulatory 
mechanism mediated by JMJD3. In this study we show, using ge­
nome­wide experiments and further molecular analysis, that JMJD3 
FIGURE 5: JMJD3 association within the body of genes depends on active transcription.(A) Immunoblot from NSCs 
using ab5095 antibody (which recognizes RNAPII-S2p isoform) in the absence (–DRB) or presence (+DRB) of 75 μM DRB 
for 4 h. Actin was used as loading control. Immunoblot using RNAPII antibody (N20; which recognizes both 
unphosphorylated [IIa] and phosphorylated [IIo] forms) was used to verify the specificity of ab5095 antibody band. 
(B) Neurogenin 2 mRNA levels in NSCs treated with TGFβ (3 h) in the absence (–DRB) or presence of DRB (+) analyzed 
by qPCR. (C) Immunostaining of NSCs with Smad3 antibody (red) before or after TGFβ treatment in the absence or 
presence of DRB. Images in blue are 4′,6-diamidino-2-phenylindole staining (DNA). (D) JMJD3 ChIP assays analyzed by 
qPCR in the absence (–DRB) or presence (+DRB) of DRB in TGFβ-stimulated NSCs (3 h). The encircled numbers above 
the scheme indicate the location of the primer sets used in the ChIP experiments. The negative control is the G6pd2 
gene. Mock signals were subtracted from specific enrichment values. Three biological replicates were used in each ChIP 
experiment. Error bars indicate SD. **p < 0.01. (E) Model for the TGFβ-dependent JMJD3 activation mechanism. The 
JMJD3 contribution to transcription regulation occurs through a two-step process. In the first step, JMJD3 is recruited 
to TGFβ-target genes by transcription factor Smad3 (Estarás et al., 2012). In the second step, JMJD3 migrates into the 
H3K27me3-enriched gene bodies to regulate the process of transcriptional elongation.
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histone H3 (ab1791; Abcam), and rabbit Smad3 (ab28379; Abcam). 
Anti­rabbit JMJD3 was kindly provided by K. Helin (Agger et al., 
2009).
Cytoplasmic and nuclear fractionation
Cell fractionation was carried out starting from 3 × 106 NSCs un­
treated or treated with TGFβ (5 ηg/ml) for 3 h. Cell pellets were 
resuspended in buffer A (10 mM Tris, 10 mM KCl, 1.5 mM MgCl2, 
and protease inhibitors) and kept on ice for 10 min. After centrifu­
gation at 1500 × g for 5 min, pellets were resuspended in buffer B 
(buffer A and 1% NP40) and incubated on ice for 5 min before cen­
trifugation at 5000 × g for 5 min. Supernatant contained the cytoso­
lic fraction. Pellet was resuspended in buffer C (20 mM Tris, 420 mM 
NaCl, 1.5 mM MgCl2, 25% glycerol, 0.2 mM EDTA, and protease 
inhibitors) by vortexing and incubating on ice. Lysates were then 
centrifuged at the highest speed for 20 min at 4°C, and supernatant 
was collected (nuclear fraction). Extracts were then used for 
Immunoblotting.
Coimmunoprecipitation and ChIP assays
Coimmunoprecipitation experiments were performed as previously 
described (Estarás et al., 2012).
Chromatin immunoprecipitation assays were essentially per­
formed as described (Frank et al., 2001; Valls et al., 2007) with modi­
fications: 3 × 106 NSCs untreated or treated with TGFβ (5 ng/ml, for 
the indicated times) were fixed with 0.2 mM di­(N­succinimidyl) glu­
tarate (Sigma­Aldrich), 45 min at room temperature, followed 
by formaldehyde 1%, 20 min. Fixation was stopped by addition of 
0.125 mM glycine. The sonication step was performed in a Bioruptor 
sonicator (12 min, 30 s on, 30 s off), and 1 mg of protein was used for 
each immunoprecipitation. Antibody–protein complex was captured 
with preblocked protein A (Amersham­Pharmacia Biotech, GE 
Healthcare Bio­Sciences, Piscataway, NJ), and DNA purification was 
carried out using Nucleospin Extract II (Macherey­Nagel, Bethlehem, 
PA) columns. ChIP DNA was analyzed by qPCR with SYBR Green 
(Roche, Indianapolis, IN) in a LightCycler 480 PCR system (Roche) 
using the primers specified in Supplemental Table S2.
ChIP-seq procedure
Chromatin immunoprecipitation and preparation of samples for se­
quencing were done essentially as previously described (Estarás 
et al., 2012). Before sequencing, ChIP DNA was prepared by simul­
taneously blunting, repairing, and phosphorylating ends according 
to manufacturer’s instructions (Illumina, San Diego, CA). The DNA 
was adenylated at the 3′ end and recovered by QIAquick PCR puri­
fication kit (Qiagen, Valencia, CA) according to the manufacturer’s 
recommendations. Adaptors were added by ligation, and the li­
gated fragments were amplified by PCR, resolved in a gel, and puri­
fied by Qiagen columns. Samples were loaded into individual lanes 
of the flow cell. We generated >26 million 36–base pair reads for 
each ChIP sample. Reads were mapped with bowtie (Langmead 
et al., 2009) to the University of California, Santa Cruz (Fujita et al., 
2011), Mus musculus genome, release 9; only sequence reads 
mapping at unique locations were kept. Peaks were called with 
SICER (Zang et al., 2009) on each sample with Input as control. 
PeakAnalyzer (Salmon­Divon et al., 2010) and CEAS (Ji et al., 2006) 
were used for peak annotation and profiling. R language and 
Bioconductor (Gentleman et al., 2004), including packages Short­
Read and IRanges (Morgan et al., 2009), were used for further 
annotation and statistical analysis.
To derive the metagene profile, we first computed the profile for 
each gene before computing the average. Specifically, we divided 
Our results show that with TGFβ, JMJD3 and RNAPII­S2p spread 
along the H3K27me3 intragenic regions to transcribe the genes and 
that in the absence of JMJD3, RNAPII­S2p is not able to progress 
through the H3K27me3­enriched genes. This suggests that 
H3K27me3 demethylation at the intragenic regions might provide 
an additional requirement to trigger transcriptional activation. It is 
also possible that other factors different from histones might be 
JMJD3 targets, such as Smads, RNAPII, or other components of the 
transcription machinery. However, the fact that JMJD3 is required to 
activate only a subset of genes in response to TGFβ suggests that 
the major JMJD3 target is not a general transcription factor. Another 
possibility is that JMJD3 (in addition to its HDM function) plays a 
demethylating­independent role for these genes, as proposed for 
other genes (Miller et al., 2010).
There are several examples of factors that spread along the tran­
scribing region of genes with RNAPII, such as the RNA processing 
machinery (Pandit et al., 2008). This is also the case for UTX, which 
is associated with the intragenic region of genes transcribed by 
RNAPII (Seenundun et al., 2010) and colocalizes with the elongating 
form of RNAPII (Smith et al., 2008). Moreover, it was recently shown 
that JMJD3 and UTX activate T­box family–dependent gene tran­
scription by interacting with Brg1 (Miller et al., 2010). Of interest, 
Brg1 facilitates transcription elongation (Subtil­Rodriguez and 
Reyes, 2010). Thus JMJD3 may promote RNAPII progression 
through the gene bodies by altering their chromatin architecture, 
by H3K27me3 demethylation of the transcribing regions, and pos­
sibly through the interaction with Brg1 or other chromatin­modify­
ing factors. It was also recently shown that JMJD3, together with 
KIAA1718 histone demethylase, promotes transcription elongation 
by contributing to the recruitment of SPT6 and SPT16 elongation 
factors to gene promoters in response to TPA (Chen et al., 2012). 
Accordingly, we show that JMJD3 contributes to the recruitment of 
the Ser2P­CTD kinase Cdk9 on the neurogenin 2 promoter. Taken 
together, these results point to multiple roles of JMJD3 in transcrip­
tion elongation probably through HDM activity–dependent and 
–independent mechanisms.
Whether the proposed JMJD3 role is specific for the TGFβ sig­
naling pathway needs further investigation. However, given the 
wide spectrum of signaling pathways that act through JMJD3 activ­
ity (Jepsen et al., 2007; De Santa et al., 2009; Akizu et al., 2010; 
Estarás et al., 2012), we postulate that it may be a general mecha­
nism to activate genes silenced by H3K27me3. Nonetheless, due to 
the regulatory function of TGFβ in developmental processes and in 
cancer, our discovery provides an additional layer for the modula­
tion of TGFβ signaling pathway outcome, targeting JMJD3 activity 
on a specific set of TGFβ­responsive genes.
MATERIALS AND METHODS
Cell culture
Human 293t cells were grown under standard conditions 
(Blanco­Garcia et al., 2009). Mouse NSCs were grown as previ­
ously described (Estarás et al., 2012).
Antibodies and reagents
TGFβ was acquired from Millipore (Billerica, MA; GF111), and DRB 
was purchased from Sigma­Aldrich (St. Louis, MO). Antibodies used 
were anti–rabbit trimethyl H3K27 (07449; Millipore), rabbit total 
RNAPII (N20; sc­899x; Santa Cruz Biotechnology, Santa Cruz, CA), 
rabbit RNAPII­S2p ChIP grade (ab5095; Abcam, Cambridge, MA), 
mouse RNAPII 8WG16 (ab817; Abcam), rabbit Cdk9 (H­169; 
sc­8338; Santa Cruz Biotechnology), goat actin (I­19; sc­1616; Santa 
Cruz Biotechnology), mouse β­tubulin (MAB3408; Millipore), rabbit 
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each gene into the same number of bins and computed the ge­
nomic sequencing read densities for each bin. Genes are scaled as 
follows: 1) ±1 kb from the TSS and ±1 kb from the TES were un­
scaled, and 2) the region within the gene body extending from TSS 
to TES was scaled to 3 kb.
mRNA extraction and qPCR
mRNA was purified with Qiagen columns following the manufac­
turer’s instructions. Reverse transcription was performed with Tran­
scriptor kit (Roche) following the manufacturer’s procedure. qPCR 
was done with SYBR Green in an LC480 LightCycler using the prim­
ers specified in Supplemental Table S2.
Indirect immunofluorescence
Indirect immunofluorescence was essentially performed as de­
scribed previously (Akizu et al., 2010).
Statistical analysis
Quantitative data are expressed as mean and SD of at least three 
biologically independent experiments. The significance of differ­
ences between groups was assessed using the Student’s t test 
(*p < 0.05; **p < 0.01).
Accession numbers
The genome­wide mapping data of H3K27me3, JMJD3, and RNAPII 
in NSCs reported in the article are available at the Gene Expression 
Omnibus server (www.ncbi.nlm.nih.gov/geo/) with the accession 
number GSE38269.
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